5 Key Takeaways

• 1

  MAPK inhibitors can enhance CAR T-cell therapy effectiveness in thyroid cancer by restoring TSHR expression on tumor cells.

• 2

  Combining MAPK inhibitors with TSHR-directed CAR T cells improved tumor control and survival in preclinical mouse models.

• 3

  TSHR expression is crucial for CAR T-cell activity, as low expression limits treatment efficacy against aggressive thyroid cancers.

• 4

  Concurrent treatment with MAPK inhibitors and CAR T cells resulted in stronger tumor control than either treatment alone.

• 5

  Further studies are planned to support a phase I trial of TSHR-directed CAR T cells combined with MAPK inhibitors.